Evidence map›Paper›PMID 40191749›Full record

ArticlePeerJ2025

Tumor marker elevations in chronic kidney disease: a retrospective study.

Liuxia You, Zhongying Xu, Qiaoling Liu, Guoming Jin, Changting Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liuxia You *Department of Clinical Laboratory, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Zhongying Xu *Department of Emergency and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, Suzhou, Jiangsu, China.
Qiaoling LiuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Guoming JinDepartment of Internal Medicine, Guli People's Hospital, Suzhou, Jiangsu, China.
Changting WangDepartment of General Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To investigate the changes in tumor markers such as carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA15-3), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), pro-gastrin-releasing peptide (proGRP), and human epididymis protein 4 (HE4) in patients with chronic kidney disease (CKD) as compared to healthy individuals, and to analyze the potential indicators that can be utilized for monitoring early renal dysfunction, was the aim of this study. Methods: This retrospective study involved 522 participants from our hospital, including 172 patients with CKD and 350 controls. CKD patients were divided into CKD1, CKD2, CKD3, CKD4, and CKD5 stages according to the estimated glomerular filtration rate (eGFR). Plasma creatinine and general clinical data were collected upon admission. Results: The level of tumor biomarkers, including carcinoembryonic antigen (CEA), CA125, CA15-3, CA19-9, NSE, proGRP, and HE4, were elevated in patients with CKD ( Conclusions: Patients with CKD have higher tumor markers, some of which are helpful for the early diagnosis of renal impairment.

Indexed as

Biomarkers, TumorRenal Insufficiency, ChronicAdultAgedAntigens, Tumor-Associated, CarbohydrateCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenCreatinineFemaleGlomerular Filtration RateHumansMaleMiddle AgedMucin-1Retrospective StudiesAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenCreatinineMucin-1WAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanChronic kidney diseaseDiagnosisTumor biomarkers

Identifiers

PMID40191749
PMCPMC11972561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.